{"id":384485,"date":"2024-09-25T00:01:00","date_gmt":"2024-09-24T22:01:00","guid":{"rendered":"https:\/\/medizinonline.com\/how-patients-benefit-most-from-osteoporosis-therapeutics\/"},"modified":"2024-09-24T22:27:32","modified_gmt":"2024-09-24T20:27:32","slug":"how-patients-benefit-most-from-osteoporosis-therapeutics","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/how-patients-benefit-most-from-osteoporosis-therapeutics\/","title":{"rendered":"How patients benefit most from osteoporosis therapeutics"},"content":{"rendered":"\n

Osteoporosis therapeutics have been proven to be effective in reducing the risk of vertebral and non-vertebral fractures. Ideally, they should be used as part of a multimodal therapy and tailored to individual patient characteristics. In view of the need for long-term treatment, particular attention must be paid to the management of rebound effects and side effects. Nowadays, it is suggested to take a break from therapy (“drug holidays”) after a few years. <\/strong><\/p>\n\n\n\n\n\n\n\n

Dr. Adrian Forster, Head Physician, Schulthess Klinik, Zurich, and Dr. Regula Capaul, General Practitioner, Zurich-Oerlikon, gave a practical insight into the complex topic of osteoporosis therapy [1].\nToday, around 20% of women and 7% of men over the age of 50 suffer from osteoporosis [2].\nIn Switzerland, this currently amounts to over 400,000 people affected.\nOsteoporosis is characterized by impaired remodelling of the bone substance and the resulting pathological microarchitecture of the bones.\nThe reduced bone density leads to an increased risk of fractures.\nOlder people and postmenopausal women are particularly affected by bone loss.\nOestrogen deficiency, underweight and lack of exercise promote the development of osteoporosis.\nThere are also a number of other risk factors.\nThe most important groups of drugs for the treatment of osteoporosis in Switzerland are antiresorptives (bisphosphonates, denosumab, raloxifene) and osteoanabolic agents (teriparatide, romosozumab) (Table 1) <\/strong>[1].\nAll of these osteoporosis drugs can reduce bone mass loss and fracture risk, albeit to varying degrees [3]. <\/p>\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

Selection of an individually suitable bisphosphonate<\/h3>\n\n\n\n

Treatment with bisphosphonates has a proven benefit for long-term therapy of 3 to 5 years [3].\nZolendronate is currently the most potent substance with the highest bone affinity, according to Dr. Forster [1].\nThere is evidence of positive effects for this substance with regard to vertebral and non-vertebral fracture risk reduction [3].\nHowever, side effects in the form of flu-like discomfort are relatively common in the first few days after a zolendronate injection, the speaker reported [1].\nHowever, these usually disappear within a few days.\nOne strategy to reduce the risk of side effects is to infuse the zolendronate rather slowly.\nFor some patients, they would allow a whole hour for this.\nIn addition, a non-steroidal anti-inflammatory drug or a painkiller based on paracetamol can be given beforehand, Dr. Forster advised [1].\nPatients should also be sufficiently hydrated before a zolendronate infusion, as bisphosphonates are largely excreted via the kidneys.\nThe speaker recommended using zolendronate only in patients with an eGFR >35 ml\/min\/1.73m2<\/sup>. <\/p>\n\n\n\n

As an alternative to zolendronate, alendronate can be considered, as in the case study (box) <\/strong>.\nIbronate is used with caution, as it has a lower bone affinity than zolendronate and alendronate and there are only data on the reduction of vertebral fracture risk, not peripheral fracture risk, according to the speaker [1]. <\/p>\n\n\n\n

Dr. Forster [1] also mentioned: “You should always correct a vitamin D deficiency before giving a bisphosphonate”.\nThis is so that the bone can be adequately remineralized [1].\nVitamin D is known to support the storage of calcium in the bones; vitamin D supplementation is simple and inexpensive to implement. <\/p>\n\n\n\n

Case study: Fragility fracture of the thoracic spine<\/strong><\/td><\/tr>
Dr. Capaul reported on the case of a 56-year-old female patient who fell at work on a slippery floor and sustained a fracture of the 12th thoracic vertebra (compression fracture).
The orthopaedic surgeon prescribed conservative treatment with a 3-point corset, physical rest, concomitant analgesic therapy and radiographic follow-up.
The patient was referred to the consultant for an osteoporosis assessment by her GP.\nThe family history revealed that the patient’s sister had osteoporosis.\nThe DEXA measurement showed osteoporosis in the lumbar spine and otherwise osteopenia.\nThe consultant decided to initiate bisphosphonate therapy.\nAt the time of the first zolendronate infusion, three months had passed since the fall.\nIn the follow-up consultation with her GP six months later, the patient stated that she did not want another Zolendronate infusion due to the side effects in the days following the infusion (sleep disturbances, feeling of tension in the head).\nIn consultation with a rheumatology specialist, the consultant decided to switch to alendronate (tablet, once a week) as an alternative, as this also had good data on the prevention of vertebral fractures.\nAlendronate proved to be well tolerated in this patient and a DEXA measurement after 2 years showed that there was no longer any osteoporosis in the lumbar spine. <\/td><\/tr>
according to [1]<\/em><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Essential measures after discontinuation of denosumab<\/h3>\n\n\n\n

Denosumab has a proven benefit for up to 3 years [3].\nStopping treatment with denosumab leads to a complete and rapid reversal of the bone-specific effects.\nTherefore, other measures to maintain bone density must be used temporarily after discontinuation (Table 2).<\/strong> It was not until around 2016 that it was realized that a bisphosphonate must be given after discontinuation of denosumab, according to Dr. Forster [1].\nZolendronate is best suited, which is simply given at the time of the due denosumab injection.\nIt is then worth measuring the remodeling parameters after 3 and 6 months in a fasting state.\nIf these rise to the top third of the premenopausal norm, a second infusion should be given straight away.\n“Only when you see that the remodeling parameters remain low are you on safe ground,” explained the speaker [1].\nOnly then can a break in therapy be considered.\nIf the remodeling parameters are not determined, zolendronate can simply be given 6 and 12 months after the last denosumab injection [1,5].\n“Two infusions are needed,” emphasized Dr. Forster [1].\nIt used to be thought that a single infusion was sufficient.\nThere are even patients in whom three infusions are necessary to adequately suppress the remodeling parameters.\nIf zolendronate is not desired or not tolerated, alendronate can be used as an alternative.\nIf treatment with denosumab is discontinued without subsequently administering a bisphosphonate, patients lose practically everything they have gained in the spine within 12 months, according to Dr. Forster [1]. <\/p>\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

Are jaw necrosis and atypical fractures preventable?<\/h3>\n\n\n\n

“Jaw necrosis and atypical fractures can be avoided, but it is relatively time-consuming,” Dr. Forster admitted [1].\nIn the case of mild osteoporosis, the speaker recommended taking a break from treatment for up to 5 years after a treatment period of 3-5 years.\nIn the case of severe osteoporosis (low T-score, fragility fracture or morphometric vertebral fractures), a shorter break of up to 2 years could be considered.\nIt is important to monitor patients during the treatment interruption, i.e. to take bone density measurements at regular intervals and to monitor bone remodeling in the laboratory.\nDepending on the results, the treatment break can be continued or a return to treatment can be considered (box). <\/strong>Regular dental check-ups are an important measure for patients with osteonecrosis of the jaw. <\/p>\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

Congress: KHM Congress Lucerne<\/em><\/p>\n\n\n\n

Literature:<\/p>\n\n\n\n

    \n
  1. “Osteoporosis”, Seminar A1, Dr. med. Adrian Forster and Dr. med. Regula Capaul, KHM Congress Lucerne, 20.06.2024.<\/li>\n\n\n\n
  2. Rheumaliga Schweiz: Osteoporose, brochure, 14th edition, 2022, www.rheumaliga.ch,<\/a>(last accessed 04.07.2024).<\/li>\n\n\n\n
  3. Obermayer-Pietsch B, F\u00f6ssl I, Dimai HP: Long-term therapy concepts for osteoporosis [Long-term treatment concepts for osteoporosis].\nInternist (Berl) 2021; 62(5): 474-485. <\/li>\n\n\n\n
  4. McClung M, et al: Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126(1): 13-20.<\/li>\n\n\n\n
  5. Tsourdi E, et al: Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 2020 Oct 26: dgaa756.<\/li>\n<\/ol>\n\n\n\n

    <\/p>\n\n\n\n

    <\/p>\n\n\n\n

    HAUSARZT PRAXIS 2024; 19(8): 44-45 (published on 23.8.24, ahead of print)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    Osteoporosis therapeutics have been proven to be effective in reducing the risk of vertebral and non-vertebral fractures. Ideally, they should be used as part of a multimodal therapy and tailored…<\/p>\n","protected":false},"author":7,"featured_media":384488,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Osteoporosis ","footnotes":""},"category":[11548,11520,11513,11297,11347,11480],"tags":[69428,71446,41158,77836,41346,77835,18662,77837,69445,71464,77838],"powerkit_post_featured":[],"class_list":["post-384485","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-cases-en","category-congress-reports","category-general-internal-medicine","category-geriatrics","category-rheumatology","tag-alendronate","tag-antiresorptives","tag-denosumab-en","tag-ibandronate-en","tag-khm-en","tag-osteoanabolic-agents-bisphosphonates","tag-osteoporosis","tag-raloxifene-teriparatide-en","tag-risedronate","tag-romosozumab-en","tag-zolendronate-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-19 02:38:02","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":384479,"slug":"comment-les-patients-tirent-le-meilleur-parti-des-traitements-de-losteoporose","post_title":"Comment les patients tirent le meilleur parti des traitements de l'ost\u00e9oporose","href":"https:\/\/medizinonline.com\/fr\/comment-les-patients-tirent-le-meilleur-parti-des-traitements-de-losteoporose\/"},"it_IT":{"locale":"it_IT","id":384473,"slug":"come-i-pazienti-traggono-i-maggiori-benefici-dai-farmaci-per-losteoporosi","post_title":"Come i pazienti traggono i maggiori benefici dai farmaci per l'osteoporosi","href":"https:\/\/medizinonline.com\/it\/come-i-pazienti-traggono-i-maggiori-benefici-dai-farmaci-per-losteoporosi\/"},"pt_PT":{"locale":"pt_PT","id":384467,"slug":"como-e-que-os-doentes-beneficiam-mais-da-terapeutica-da-osteoporose","post_title":"Como \u00e9 que os doentes beneficiam mais da terap\u00eautica da osteoporose","href":"https:\/\/medizinonline.com\/pt-pt\/como-e-que-os-doentes-beneficiam-mais-da-terapeutica-da-osteoporose\/"},"es_ES":{"locale":"es_ES","id":384461,"slug":"como-se-benefician-mas-los-pacientes-de-la-terapeutica-de-la-osteoporosis","post_title":"C\u00f3mo se benefician m\u00e1s los pacientes de la terap\u00e9utica de la osteoporosis","href":"https:\/\/medizinonline.com\/es\/como-se-benefician-mas-los-pacientes-de-la-terapeutica-de-la-osteoporosis\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/384485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=384485"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/384485\/revisions"}],"predecessor-version":[{"id":386928,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/384485\/revisions\/386928"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/384488"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=384485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=384485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=384485"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=384485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}